Asset Details
Do you wish to reserve the book?
Mucinous colorectal adenocarcinoma: clinical pathology and treatment options
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mucinous colorectal adenocarcinoma: clinical pathology and treatment options
Do you wish to request the book?
Mucinous colorectal adenocarcinoma: clinical pathology and treatment options
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mucinous colorectal adenocarcinoma: clinical pathology and treatment options
2019
Overview
Mucinous colorectal adenocarcinoma is a distinct subtype of colorectal cancer (CRC) characterized by the presence of abundant extracellular mucin which accounts for at least 50% of the tumor volume. Mucinous colorectal adenocarcinoma is found in 10%–20% of CRC patients and occurs more commonly in female and younger patients. Moreover, mucinous colorectal adenocarcinoma is more frequently located in the proximal colon and diagnosed at an advanced stage. Based on its molecular context, mucinous colorectal adenocarcinoma is associated with the overexpression of mucin 2 (MUC2) and mucin 5AC (MUC5AC) proteins. At the same time, it shows higher mutation rates in the fundamental genes of the RAS/MAPK and PI3K/Akt/mTOR pathways. Mucinous colorectal adenocarcinoma also shows higher rates of microsatellite instability (MSI) than non-mucinous colorectal adenocarcinoma which might correlate it with Lynch syndrome and the CpG island methylator phenotype. The prognosis of mucinous colorectal adenocarcinoma as to non-mucinous colorectal adenocarcinoma is debatable. Further, the impaired responses of mucinous colorectal adenocarcinoma to palliative or adjuvant chemotherapy warrant more studies to be performed for a specialized treatment for these patients. In this review, we discuss the molecular background and histopathology of mucinous colorectal adenocarcinoma, and provide an update on its prognosis and therapeutics from recent literatures.
Publisher
BioMed Central,John Wiley & Sons, Inc,Wiley
Subject
/ Adenocarcinoma, Mucinous - diagnostic imaging
/ Adenocarcinoma, Mucinous - genetics
/ Adenocarcinoma, Mucinous - pathology
/ Adenocarcinoma, Mucinous - therapy
/ Biomedical and Life Sciences
/ Colorectal Neoplasms - diagnostic imaging
/ Colorectal Neoplasms - genetics
/ Colorectal Neoplasms - pathology
/ Colorectal Neoplasms - therapy
/ Humans
/ Hyperthermic intraperitoneal chemotherapy
/ MUC2
/ MUC5AC
/ Mutation
/ Oncology
/ Review
